The administration of ??2-agonists for paediatric asthma and its adverse reaction in Australian and New Zealand emergency departments: a cross-sectional survey
Authors:
- Lawrence T. LamLLLawrence T. Lam
- Gary J. BrowneGBGary J. Browne
- 1 September 2003
- journal article
- Published by Wolters Kluwer Health in European Journal of Emergency Medicine
- Vol. 10 (3) , 219-224
Abstract
To determine the current use of beta2-agonists, in particular salbutamol, for the management of acute asthma in children in emergency departments throughout Australia and New Zealand. A cross-sectional survey using a questionnaire that sought to determine the current use of salbutamol and any adverse drug reactions in paediatric emergency departments. Out of 37 hospitals eligible as paediatric emergency departments, 33 (89.1%) responded to the survey, 54.5% having guidelines for the management of acute asthma. Of the paediatric emergency departments surveyed, 45.5% used metered-dose inhaler spacer combination in the treatment of mild to moderate asthma. All paediatric emergency departments used nebulized salbutamol for acute severe asthma. In addition, 85% of paediatric emergency departments used continuous-infusion intravenous salbutamol in unresponsive patients, 63.6% administering a single-dose intravenous salbutamol bolus before commencing the infusion. District paediatric emergency departments were more likely to treat with continuous-infusion intravenous salbutamol outside of the intensive care unit. Clinical unresponsiveness to inhaled salbutamol and clinical improvement were the reported criteria in all paediatric emergency departments for the use and cessation of intravenous salbutamol. Adverse drug reactions were common: tremor (90%), hypokalaemia (45.5%) and supraventricular tachycardia (21%), particularly if continuous-infusion intravenous salbutamol administered. Eight deaths from asthma were reported, none being related to adverse drug reactions. We report a wide variation of salbutamol use in paediatric emergency departments and a high prevalence of type A adverse drug reactions when continuous-infusion intravenous salbutamol therapy was administered. More evidence is needed on the clinical significance of the adverse effects reported in this study and optimal doses for the safe use of continuous-infusion intravenous salbutamol therapy in paediatric emergency departments.Keywords
This publication has 22 references indexed in Scilit:
- Spacer compliance after discharge following a mild to moderate asthma attackArchives of Disease in Childhood, 2002
- A randomised controlled trial to assess the relative benefits of large volume spacers and nebulisers to treat acute asthma in hospitalArchives of Disease in Childhood, 1999
- Cardiac side effects of long-acting beta-2 agonist salmeterol in asthmatic childrenPediatrics International, 1999
- INCREASE IN ASTHMA SEVERITY IN THE WESTJournal of Paediatrics and Child Health, 1997
- Hypokalaemia following nebulized salbutamol in children with acute attack of bronchial asthmaJournal of Paediatrics and Child Health, 1996
- Efficacy and Side Effects of Beta2-Agonists by Inhaled Route in Acute Asthma in Children: Comparison of Salbutamol, Terbutaline, and FenoterolJournal of Asthma, 1996
- Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthmaThe Journal of Pediatrics, 1993
- Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home.Archives of Disease in Childhood, 1990
- Improvement in clinical asthma score and Paco2 in children with severe asthma treated with continuously nebulized terbutalineJournal of Allergy and Clinical Immunology, 1988
- Intravenous salbutamol in the treatment of status asthmaticus in childrenCritical Care Medicine, 1984